Dr. Reddy's faces revenue slowdown post gRevlimid boost, but new investments and partnerships offer long-term growth ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

According to the Vietnam Administration of Disease Prevention, in the 40 years of organising and implementing the National Expanded Programme on Immunisation since 1985, Vietnam has achieved several ...

Sublime’s award is just one of the 24 that were rolled back after U.S. Secretary of Energy Chris Wright announced the awards ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...